The new ITF Therapeutics headquarters designed to support the rare disease community.
Want to target the right audience? Sponsor our site and choose your specific industry to connect with a relevant audience.
Prominent brand mentions across targeted, industry-focused articles
High-visibility placements that speak directly to an engaged local audience
Guaranteed coverage that maximizes exposure and reinforces your brand presence
Interested in seeing what sponsored content looks like on our platform?
May’s Roofing & Contracting
Forwal Construction
NSC Clips
Real Internet Sales
Suited
Florida4Golf
Click the button below to sponsor our articles:
Sponsor Our ArticlesITF Therapeutics LLC has inaugurated its new U.S. headquarters in Concord, Massachusetts, dedicated to advancing treatment for Duchenne muscular dystrophy (DMD) and rare diseases. The 10,000 square foot facility aims to foster collaboration and accommodate growth with plans for up to 40 team members. The company’s new product, DUVYZAT™, which targets DMD, has received FDA approval, promising hope for families. With a focus on accessibility, patient advocacy, and innovative therapies, ITF aims to enhance care and support within the DMD community.
Big news on the horizon as ITF Therapeutics LLC has officially opened its new U.S. headquarters! Nestled in the heart of Concord, Massachusetts, this brand-new facility is set to make waves in the world of Duchenne muscular dystrophy (DMD) and other rare diseases. Mark your calendars for March 5, 2025—this date is sure to be a milestone for the community!
The new headquarters, spanning a whopping 10,000 square feet, is located at 575 Virginia Road, Unit 201. With plenty of room to grow, this central hub will house corporate offices and meeting spaces designed specifically for the DMD community and other rare disease advocates.
Under the leadership of President Matt Trudeau, ITF Therapeutics is on a fast track for growth. The company, which was established in January 2024, is dedicated to making a meaningful impact on the lives of those impacted by rare diseases. With plans to accommodate up to 40 team members, the headquarters fosters a collaborative working environment, all aimed at improving patient care.
An important aspect of the new headquarters is its thoughtful design. ITF has worked closely with patient advocacy leaders to create a space that not only meets corporate needs but also enhances accessibility and comfort for all guests. This approach demonstrates a clear commitment to understanding the challenges faced by the DMD community.
ITF Therapeutics isn’t just stopping at opening an impressive headquarters. Their pioneering product, DUVYZAT™ (givinostat), received FDA approval and launched commercially on March 21, 2024. This innovative treatment targets DMD in patients aged six and older, marking a significant advancement in the fight against this debilitating disease.
The FDA approval process for DUVYZAT was buttressed by the positive results found in the EPIDYS clinical trial. Findings from the trial showed a substantial improvement in physical mobility in patients compared to those who received a placebo. While the treatment does have some side effects, such as diarrhea, nausea, vomiting, and low platelet counts, it still represents hope for many families affected by DMD.
In addition to providing transformative therapies, ITF Therapeutics is launching a comprehensive patient services program called ITF ARC. This program is designed to assist patients and their families with navigating the complex world of treatment access, insurance, and more—because no one should have to face this journey alone.
To ensure smooth operations and strategic growth, Erica L. Monaco has joined the ranks as the Chief Operating Officer. With her at the helm, ITF Therapeutics is well-equipped to tackle the challenges of rare diseases and to forge valuable partnerships within the community.
As the headquarters opens its doors, the focus will remain on collaboration—particularly with patient advocacy groups. ITF Therapeutics aims to keep a finger on the pulse of the community’s needs to ensure that they are met within the company’s programs.
The establishment of this new headquarters in Concord symbolizes not just the growth of ITF Therapeutics, but also a renewed hope for the DMD community. Each step taken here is another leap towards making lives better—one patient at a time. Here’s to the exciting journey ahead!
Hospital Kuala Lumpur Marks Malaysia’s First Rare Disease Day
ITF Therapeutics Launches New U.S. Headquarters
News Summary Al Williams, a candidate for the Michigan Democratic Party leadership, has stirred controversy…
News Summary Kevin Brick, owner of Maxim Tickets, Inc., has filed a lawsuit against the…
News Summary Senator Elissa Slotkin addressed an audience in Wyandotte, Michigan, articulating a sharp critique…
News Summary Apple has achieved a remarkable feat by being named the World's Most Admired…
News Summary Volvo Cars' CEO expresses disappointment over the EU's decision to extend CO2 emissions…
News Summary Virgin Group, led by Richard Branson, is set to invest £700 million to…